Plasma Levels of Soluble AβPPβ as a Biomarker for Alzheimer’s Disease with Dementia

Cost- and time-effective markers of Alzheimer’s disease (AD), reliable and feasible at the population level are urgently needed. Soluble amyloid-β protein precursor β (sAβPPβ) in plasma has attracted scientific attention as a potential AD biomarker candidate. Here we report that plasma sAβPPβ levels in patients with AD dementia and typical for AD cerebrospinal fluid (CSF) biomarker profiles (N = 33) are significantly lower (p < 0.01) than those of cognitively healthy elderly individuals without AD (N = 39), while CSF sAβPPβ levels did not differ between the studied groups. This provides further evidence for the potential of sAβPPβ in plasma as an AD biomarker candidate.

• Publication year

  2019

• Venue

  Journal of Alzheimer's Disease

• Publication date

  2019-03-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.3233/JAD-181088PMID 30909232
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Challenges associated with biomarker-based classification systems for Alzheimer's disease

  2018cited by this paper
• Synergistic interaction between APOE and family history of Alzheimer’s disease on cerebral amyloid deposition and glucose metabolism

  2018cited by this paper
• Plasma β-amyloid1-42 reference values in cognitively normal subjects.

  2018cited by this paper
• Cerebrospinal Fluid BACE1 Activity and sAβPPβ as Biomarker Candidates of Alzheimer’s Disease

  2018cited by this paper
• Soluble Amyloid Precursor Proteins in Blood: Methods and Challenges

  2018cited by this paper
• High performance plasma amyloid-β biomarkers for Alzheimer’s disease

  2018cited by this paper
• Amyloid blood biomarker detects Alzheimer's disease

  2018cited by this paper
• Plasma Amyloid-β (Aβ42) Correlates with Cerebrospinal Fluid Aβ42 in Alzheimer’s Disease

  2018cited by this paper
• Potential value of soluble APPα and APPβ in CSF as biomarkers of dementia disorders: Unresolved issues and perspectives

  2018cited by this paper
• NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease

  2018cited by this paper
• Cerebrospinal Fluid Biomarkers of Preclinical Alzheimer’s Disease

  2018cited by this paper
• Imaging Biomarkers in Alzheimer’s Disease: A Practical Guide for Clinicians

  2017cited by this paper
• Plasma levels of soluble amyloid precursor protein β in symptomatic Alzheimer’s disease

  2017cited by this paper
• CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

  2017cited by this paper
• Blood‐based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic

  2017cited by this paper
• Re-evaluation of soluble APP-α and APP-β in cerebrospinal fluid as potential biomarkers for early diagnosis of dementia disorders

  2017cited by this paper
• A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain

  2017cited by this paper
• Clinical validity of CSF biomarkers for Alzheimer's disease: necessary indeed, but sufficient?

  2016cited by this paper
• Mapping CSF biomarker profiles onto NIA–AA guidelines for Alzheimer’s disease

  2016cited by this paper
• Association between Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer’s Disease

  2016cited by this paper
• CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.

  2016cited by this paper
• Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.

  2015cited by this paper
• Soluble amyloid precursor proteins and secretases as Alzheimer's disease biomarkers.

  2014cited by this paper
• Cerebrospinal fluid BACE1 activity and markers of amyloid precursor protein metabolism and axonal degeneration in Alzheimer's disease

  2014cited by this paper
• Clearance of Amyloid-Beta in Alzheimer’s Disease: Shifting the Action Site from Center to Periphery

  2014cited by this paper
• Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.

  2014cited by this paper
• Amyloid Cascade and Tau Pathology Cerebrospinal Fluid Markers in Mild Cognitive Impairment with regards to Alzheimer's Disease Cerebral Metabolic Signature

  2013cited by this paper
• Soluble amyloid precursor protein α and β in CSF in Alzheimer's disease.

  2013cited by this paper
• Impact of the 2008–2012 French Alzheimer Plan on the Use of Cerebrospinal Fluid Biomarkers in Research Memory Center: The PLM Study

  2013cited by this paper
• Soluble amyloid precursor protein β as blood-based biomarker of Alzheimer's disease

  2013influential reference
• Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis.

  2012cited by this paper
• An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease

  2012cited by this paper
• Cerebrospinal Fluid Soluble Amyloid-β Protein Precursor as a Potential Novel Biomarkers of Alzheimer's Disease

  2012cited by this paper
• Cerebrospinal Fluid Profiles of Amyloid β-Related Biomarkers in Alzheimer’s Disease

  2012cited by this paper
• Cerebrospinal Fluid Levels of sAPPα and sAPPβ in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates

  2011cited by this paper
• Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex

  2011cited by this paper
• The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease

  2010cited by this paper
• Plasma and cerebrospinal fluid Levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease

  2000cited by this paper
• Standardization of measurement of β-amyloid(1-42) in cerebrospinal fluid and plasma

  2000cited by this paper
• Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

  2000cited by this paper
• Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF

  1999cited by this paper
• Detection of Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Sensitive Sandwich Enzyme‐Linked Immunosorbent Assay

  1993cited by this paper
• Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay.

  1993cited by this paper
• Apolipoprotein E genotyping by one-stage PCR.

  1991cited by this paper
• Estimation of Relationships for Limited Dependent Variables

  1958cited by this paper

• No citing papers are available for this paper.